Shilpa Medicare Enters Monetisation Phase

Shilpa Medicare spent ₹800 crore on R&D and ₹1,200 crore on capex between FY21-FY25. The payoff is now showing formulation revenue surged 74% to ₹498 crore and biologics revenue more than doubled to ₹151 crore in FY26. Total revenue grew nearly 20%. Shilpa started as a low-margin API ingredient supplier for cancer drugs. Now it is moving into biosimilars, complex formulations and CDMO services all high-margin businesses that require deep R&D expertise that competitors cannot easily replicate. This is a classic move up the pharma value chain. Companies that spend consistently on R&D Shilpa spends 8% of annual revenue eventually reach a monetisation phase where past investments start generating premium revenue. The longer and harder the investment phase the stronger the competitive moat built. Shilpa Medicare's monetisation phase taught me that pharma companies consistently investing in R&D and moving from APIs to biosimilars and CDMO unlock significantly higher margins over time, making it essential to track R&D spending intensity and revenue mix shifts for pharma stocks like $SHILPAMED Shilpa, $DIVISLAB Divi's Labs and $LAURUSLABS Laurus Labs before investing.